Acetyl Hexapeptide-3 (Argireline)
Acetyl Hexapeptide-3 (Argireline) research profile covering evidence quality, proposed mechanisms, safety considerations, regulatory status, and linked…
Evidence-led profile
Research snapshot
- Evidence stage
- Emerging research
- References
- 4 linked sources
- Research coverage
- 2 areas
- Editorial review
- Mar 8, 2026
Published by the PepGuide Editorial Team using our research methodology.
Overview
Argireline was developed as a topical alternative to botulinum toxin injections for reducing facial expression lines. It targets the same SNARE machinery involved in synaptic vesicle fusion but acts through competitive inhibition rather than enzymatic cleavage. Clinical studies using topical formulations at 5-10% concentrations have demonstrated measurable reductions in periorbital and glabellar wrinkle depth after 28-30 days of twice-daily application.
The peptide is incorporated into a wide range of commercial anti-aging products including serums, creams, and emulsions. Its non-invasive delivery and favorable safety profile make it one of the most commercially successful cosmetic peptides.
Mechanism of Action
Argireline mimics the N-terminal end of SNAP-25, one of three proteins forming the SNARE complex required for synaptic vesicle docking and fusion. By competing with native SNAP-25 for incorporation into the ternary SNARE complex, it destabilizes the assembly and reduces catecholamine and acetylcholine release from presynaptic terminals. This decreases the frequency and intensity of muscle contractions at the neuromuscular junction, particularly in facial muscles responsible for dynamic expression lines.
Unlike botulinum neurotoxins, which cleave SNARE proteins irreversibly, Argireline acts as a reversible competitive inhibitor. This distinction underlies its milder effect profile and suitability for topical cosmetic use. Bhargava et al. demonstrated that the SNAP-25 fragment approach modulates exocytosis without disrupting basal neurotransmission.
Research
Anti-Wrinkle Effects
In a pivotal open-label study, Blanes-Mira et al. (2002) demonstrated that a 10% Argireline emulsion applied twice daily for 30 days reduced periorbital wrinkle depth by approximately 30% compared to a placebo emulsion. Silicone replica analysis confirmed statistically significant smoothing of expression lines.
A subsequent study combining Argireline (5% solution, 0.05% active) with Leuphasyl (pentapeptide targeting the pre-synaptic membrane) in a twice-daily regimen over 28 days showed a mean wrinkle depth reduction of 24.6%, with individual improvements up to 46.5%. The additive effect was attributed to complementary mechanisms at different stages of neurotransmitter release.
Wang et al. (2013) investigated the penetration-enhancing strategies for Argireline delivery through the stratum corneum, finding that nanostructured lipid carriers improved skin retention and efficacy compared to conventional formulations.
Neuromuscular Modulation
In vitro studies using chromaffin cell models demonstrated that Argireline inhibits catecholamine release in a dose-dependent manner, confirming its mechanism of SNARE complex disruption at the cellular level. Blanes-Mira et al. (2002) showed that the hexapeptide reduced stimulated exocytosis by interfering with the formation of the ternary SNARE complex without affecting cell viability.
Electrophysiological studies have confirmed that the peptide's effect is reversible and dose-dependent, with no evidence of permanent neuromuscular blockade -- a key safety differentiator from botulinum toxin.
Safety and Limitations
Topical application of Argireline at concentrations up to 10% is generally well-tolerated with no significant adverse effects reported in published clinical studies. Dermal irritation testing shows minimal sensitization potential. No systemic effects have been observed, consistent with the peptide's limited transdermal absorption and local mechanism of action. The reversible nature of SNARE complex inhibition provides an additional safety margin compared to neurotoxin-based alternatives.
Research protocol summary
- Route
- Topical (cream, serum)
These values summarize cataloged research protocols. They are not personal dosing instructions or medical guidance.
Reconstitution Calculator
Pharmacokinetic Profile
Acetyl Hexapeptide-3 (Argireline) — Pharmacokinetic Curve
Topical (cream, serum)Molecular Structure
- Formula
- C34H60N14O12S
- Weight
- 888.99 Da
- CAS
- 616204-22-9
- PubChem CID
- 11390410
- Exact Mass
- 221.1528 Da
- LogP
- 0.7
- TPSA
- 70.1 Ų
- H-Bond Donors
- 1
- H-Bond Acceptors
- 3
- Rotatable Bonds
- 3
- Complexity
- 359
Identifiers (SMILES, InChI)
InChI=1S/C12H19N3O/c1-3-8(2)10(14)11(16)15-5-4-9-6-12(9,15)7-13/h8-10H,3-6,14H2,1-2H3/t8-,9+,10-,12+/m0/s1
VFMGPTHTVPHION-MIZYBKAJSA-NResearch Protocols
topical
Overview Argireline was developed as a topical alternative to botulinum toxin injections for reducing facial expression lines. Clinical studies using topical formulations at 5-10% concentrations have demonstrated measurable reductions in periorbital and glabellar wrinkle depth after 28-30 days of t
transdermal Injection
No systemic effects have been observed, consistent with the peptide's limited transdermal absorption and local mechanism of action.
Reported Research Timeline
A subsequent study combining Argireline (5% solution, 0.05% active) with Leuphasyl (pentapeptide targeting the pre-synaptic membrane) in a...
Clinical studies using topical formulations at 5-10% concentrations have demonstrated measurable reductions in periorbital and glabellar wrinkle...
Continued use as directed
Quality Indicators
What to look for
- Well-established safety profile
Frequently Asked Questions
References (4)
- [5]
- [2]Wang Y et al Enhanced skin permeation of Argireline through nanostructured lipid carriers J Biomed Nanotechnol (2013)
- [3]Kraeling MEK et al In vitro skin penetration of acetyl hexapeptide-8 from cosmetic formulations Cutan Ocul Toxicol (2015)
- [1]Blanes-Mira C et al A synthetic hexapeptide (Argireline) with antiwrinkle activity Int J Cosmet Sci (2002)
Continue researching Acetyl Hexapeptide-3 (Argireline)
Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.